We cover
					
			ASCO GU | Genitourinary Cancers Symposium
ASCO GU 2024
ASCO GU 2025
Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC
				 / Cherrishe Brown-Bickerstaff / Jan Andreasen			
			
		Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer
				 / Deniz Tural / Jan Andreasen			
			
		Real-Life Data Confirms Avelumab Maintenance Benefits in Metastatic Urothelial Carcinoma
				 / Deniz Tural / Jan Andreasen			
			
		Cabozantinib Real-World Effectiveness in the Second-Line Setting of Metastatic Renal Cell Carcinoma
				 / Martin Zarba / Jan Andreasen			
			
		Danish Study Reveals Doubling of Kidney Cancer Cases and a Growing Gender Gap
				 / Johanne Ahrenfeldt / Jan Andreasen			
			
		ASCO GU 2024
Cancer Epigenomics Improve the Overall Survival and the Quality of Life
				 / Marc Eid / Karl Semaan			
			
		Real-World Data on Avelumab as 1L Maintenance Treatment
				 / Philippe Barthelemy			
			
		News from ASCO GU 2023
Meet the experts • Uro Oncology 2023 • Meet the experts
ASCO GU 2022 and 2023
Lisää uutisia ASCO GU 2021 -symposiumista
Management of Erdafitinib, a pan-FGFR kinase inhibitor, treatment-emergent adverse events
				 / Arlene O. Siefker-Radtke			
			
		 
		
 
			
 
			 
			 
			
 
			


 
			

 
			





 
			


 
			 
			







 
			  		 
			 
			



 
			
 
			 
			 
			


